,subjsummary,subj,rel,obj,objsummary,ref
0,depression,depression,definition,a prevalent psychiatric disorder that often leads to poor quality of life and impaired functioning,disorder,"""depression is a prevalent psychiatric disorder that often leads to poor quality of life and impaired functioning."""
1,ssris,selective serotonin reuptake inhibitors (ssris),first-line treatment,depression,depression,"""pharmacotherapy, especially selective serotonin reuptake inhibitor antidepressants, remain the most frequent option for treating depression during the acute phase"""
2,maois,monoamine oxidase inhibitors (maois),definition,a class of antidepressant drugs,antidepressants,"""iproniazid was later classified as a monoamine oxidase inhibitor (maoi)"""
3,maois,monoamine oxidase inhibitors (maois),less commonly used,over time for treating depression,depression,"""consequently, maois have become less commonly used over time"""
4,depression with atypical features,depression with atypical features,subset,depression,depression,"""maois have demonstrated specific efficacy in treating depression with atypical features"""
5,maois,monoamine oxidase inhibitors (maois),specific efficacy in treating,depression with atypical features,atypical depression,"""maois have demonstrated specific efficacy in treating depression with atypical features"""
6,ect,electroconvulsive therapy (ect),highly effective,depression,depression,"""electroconvulsive therapy is the most effective somatic therapy for depression in some specific situations"""
0,ssris,selective serotonin reuptake inhibitors (ssris),first-line treatment,major depressive disorder (mdd),mdd,"therefore, most guidelines currently recommend ssris as the first-line treatment for patients with major depression."
1,tca,tricyclic antidepressants (tca),more effective,selective serotonin reuptake inhibitors (ssris),ssris,"however, some tcas can be more effective than ssris when used to treat hospitalized patients."
2,snris,serotonin-norepinephrine reuptake inhibitors (snris),second-line treatment,patients who do not respond to ssris,patients unresponsive to ssris,clinical guidelines commonly recommend prescribing snri to patients who do not respond to ssris.
3,ketamine,ketamine,side effects,"dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting,  cardiovascular symptoms",diverse,"common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms."
4,ssris,selective serotonin reuptake inhibitors (ssris),comparable to,tricyclic antidepressants (tca),tca,"in most systematic reviews and meta-analyses, ssris have demonstrated comparable efficacy to tcas."
5,venlafaxine,venlafaxine,comparable to,tricyclic antidepressants (tca),tca,"also, venlafaxine’s efficacy is comparable to that of tcas."
6,ssris,selective serotonin reuptake inhibitors (ssris),side effects,"sexual and digestive (nausea and loss of appetite), as well as irritability, anxiety, insomnia, and headache",multiple,"currently available ssris include fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram. they have elicited different tolerance rates and side effects - mostly sexual and digestive (nausea and loss of appetite), as well as irritability, anxiety, insomnia, and headache."
7,bupropion,bupropion,specific efficacy in treating,major depressive disorder (mdd) in individuals with low to moderate level of anxiety,mdd in individuals with anxiety,"for individuals with low to moderate levels of anxiety, the efficacy of bupropion in treating mdd is comparable to that of ssris."
8,trazodone,trazodone,widely used,as a sedative-hypnotic more than as an antidepressant,sedative-hypnotic,"in contemporary practice, it is much more likely to be used in low dose as a sedative-hypnotic than as an antidepressant."
9,mirtazapine,mirtazapine,comparable to,selective serotonin reuptake inhibitors (ssris),ssris,mirtazapine is about as effective as ssris.
10,vortioxetine,vortioxetine,benefits,depression-related cognitive impairment,cognitive impairment,"in the specific case of vortioxetine, have particular benefit in depression-related cognitive impairment."
11,esketamine,esketamine,approved by,the united states food and drug administration (fda) in march 2019 for treatment-resistant depression,fda for trd,it has been approved by the united states food and drug administration in march 2019 for treatment-resistant depression.
0,maoi,monoamine oxidase inhibitor (maoi),definition,a class of antidepressants,antidepressants,monoamine oxidase inhibitor (maoi) confirmed the role of monoaminergic transmission in depression.
1,imipramine,imipramine,example,tricyclic antidepressant (tca),tca,"imipramine, desipramine, nortriptyline, and amitriptyline are tcas."
2,ssri,selective serotonin reuptake inhibitor (ssri),definition,a class of antidepressants,antidepressants,selective serotonin reuptake inhibitor (ssri) improved tolerability.
3,snri,serotonin-norepinephrine reuptake inhibitor (snri),definition,a class of antidepressants,antidepressants,serotonin-norepinephrine reuptake inhibitor (snri) is commonly recommended for patients who do not respond to ssris.
4,esketamine,esketamine,treats,treatment-resistant depression,treatment-resistant depression,esketamine is used for treatment-resistant depression with a great affinity for nmda receptors than ketamine.
5,cbt,cognitive-behavioral therapy (cbt),definition,a psychotherapeutic intervention,psychotherapeutic intervention,cognitive-behavioral therapy (cbt) targets depressed patients' irrational beliefs and distorted cognitions that perpetuate depressive symptoms.
6,cbasp,cognitive behavioral analysis system of psychotherapy (cbasp),first-line treatment,chronic depression,chronic depression,the european psychiatric association recommends using the cognitive behavioral analysis system of psychotherapy (cbasp) for treating chronic depression.
7,psychotherapy,psychotherapy,overview,"combines elements of cbt with interpersonal therapy, supportive therapy, and psychoeducational intervention",comprehensive approach,overview of psychotherapy in depression describes the combination of different psychotherapeutic interventions.
8,ssri,selective serotonin reuptake inhibitor (ssri),side effects,"sexual dysfunction, loss of appetite, vomiting, nausea, irritability, anxiety, insomnia, headache",side effects,"ssris improve tolerability but have several minor side effects such as sexual dysfunction, loss of appetite, vomiting, nausea, irritability, anxiety, insomnia, and headache."
9,mdd,major depressive disorder (mdd),associated with,delay in clinical onset of antidepressant effects,delayed antidepressant effect,"study show an acute increase in monoamine in the synaptic cleft immediately following treatment, even when the depletion of tryptophan does not induce depressive-like behavior in healthy humans. this finding shows that research on the pharmacological options for treating depression must go beyond monoaminergic neurotransmission systems."
0,cbt,cognitive-behavioral therapy (cbt),first-line treatment,mild to moderate major depressive disorder,mdd,"cbt, be a first-line treatment for mild to moderate major depressive episode in adult;"
1,ipt,interpersonal therapy (ipt),first-line treatment,mild to moderate major depressive disorder,mdd,"ipt, like cbt, be a first-line treatment for mild to moderate major depressive episode in adult;"
2,pst,problem-solving therapy (pst),comparable to,other psychotherapeutic methods used to treat depression,other methods,pst be comparable to other psychotherapeutic method use to treat depression
3,mft,marital and family therapy (mft),treats,some aspects of major depressive disorder,mdd,marital and family therapy (mft) be effective in treat some aspect of depression.
4,cbt,cognitive-behavioral therapy (cbt),treats,major depressive disorder with comorbid personality disorders,mdd with comorbidities,"schema therapy be another cbt-derive therapy that can be use in patient who have fail classical cbt, like patient with personality disorder comorbidity."
5,mbct,mindfulness-based cognitive therapy (mbct),benefits,patients at high risk of relapse,high risk patients,"it be a potential alternative to reduce, or even stop, antidepressant treatment without increase the risk of depressive recurrence, especially for patient at a high risk of relapse."
6,physical exercise,physical exercise,associated with,improvement in quality of life for patients with major depressive disorder,quality of life,exercise also promote improvement in one’s quality of life in general.
7,psycho-education,psycho-education,definition,intervention educating depressed patients and their families about symptoms and management of major depressive disorder,intervention,psycho-education: this type of intervention educate depress patient and (with their permission) family member involve in the patient’s life about depression symptom and management.
0,psychotherapy,psychotherapy,treats,all depression,all depression,although psychotherapy be effective for treat depression and improve patient’s quality of life
1,ect,electroconvulsive therapy (ect),definition,a treatment for resistant depression,resistant depression treatment,ect be the most well-know treatment for resistant depression
2,ect,electroconvulsive therapy (ect),highly effective,major unipolar depression,mud,"ect be arguably the most effective treatment modality in psychiatry, and its superiority over pharmacotherapy for major unipolar depression be widely support"
3,rtms,repetitive transcranial magnetic stimulation (rtms),definition,a type of biological stimulation that affects brain metabolism and neuronal electrical activity,biological stimulation,"this method, which be a type of biological stimulation that affect brain metabolism and neuronal electrical activity"
4,rtms,repetitive transcranial magnetic stimulation (rtms),more effective,placebo condition,placebo,treatment combine rtms and antidepressant be significantly more effective than placebo condition
5,tdcs,transcranial direct current stimulation (tdcs),definition,a technique that delivers weak current to the brain via electrodes placed on the scalp,brain stimulation technique,tdcs this technique deliver weak current to the brain via electrode place on the scalp
6,tdcs,transcranial direct current stimulation (tdcs),less effective,antidepressants and rtms,"antidepressants, rtms",its effect remain low than that of antidepressant and rtms
7,vns,vagus nerve stimulation (vns),definition,a therapeutic method used for resistant unilateral or bipolar depression,resistant depression treatment,vns be a therapeutic method that have be use for the last sixteen year to treat resistant unilateral or bipolar depression
8,dbs,deep brain stimulation (dbs),definition,stimulation of subgenual cingulate white matter for resistant depression,resistant depression treatment,"accord to the literature, dbs of the subgenual cingulate white matter (brodmann area = ba 25) elicit a clinical response in 60% of resistant depression patient after six month"
9,mst,magnetic seizure therapy,definition,a technique to induce a therapeutic seizure with magnetic stimulation under anesthesia,therapeutic seizure induction,magnetic seizure therapy involve induce a therapeutic seizure by apply magnetic stimulation to the brain while the patient be under anesthesia
10,phototherapy,phototherapy,definition,depression treatment using intense light exposure,depression treatment,the first description of reduced depression symptom due to intense light exposure be present in 1984
11,neuro-modulation treatments,neuro-modulation treatments,treatment options,all depression,all depression,neuro-modulation treatment offer a range of treatment option for patient with depression
0,resistant depression,resistant form of depression,treats,"combination of medication, psychotherapy, and somatic therapy",combination therapy,"combination of medication, psychotherapy, and somatic therapy remain the most effective way to manage resistant form of depression."
1,ect,electroconvulsive therapy (ect),first-line treatment,certain forms of depression,specific depressions,ect is the only somatic treatment with confirmed indications for certain forms of depression.
2,antidepressants,antidepressants,subset,treatment options for depression,depression treatments,"the three principal methods available to caregivers are antidepressants, specifically structured psychotherapy, and somatic approaches."
3,psychotherapy,structured psychotherapy,subset,treatment options for depression,depression treatments,"the three principal methods available to caregivers are antidepressants, specifically structured psychotherapy, and somatic approaches."
4,somatic approaches,somatic approaches,subset,treatment options for depression,depression treatments,"the three principal methods available to caregivers are antidepressants, specifically structured psychotherapy, and somatic approaches."
5,gaba regulation,gamma-aminobutyric acid (gaba) regulation,associated with,research on depression pharmacotherapy,pharmacotherapy research,research on depression pharmacotherapy continues to examine new molecules implicated in gamma-aminobutyric acid regulation.
6,glutamate transmission,glutamate transmission,associated with,research on depression pharmacotherapy,pharmacotherapy research,research on depression pharmacotherapy continues to examine new molecules implicated in glutamate transmission.
7,psychotherapeutic interventions,psychotherapeutic interventions,goal,to personalize and simplify,personalization and simplification,"also, efforts to personalize and simplify psychotherapeutic interventions are ongoing."
8,somatic interventions,somatic intervention protocols,requirements,further study and specification of indications,study & specification,"protocols using somatic interventions need to be studied in more depth, and their indications must be specified."
0,inhibition,inhibition of hepatobiliary transport,results,clinical hepatotoxicity of nefazodone,hepatotoxicity,"""inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone."""
1,ketamine,ketamine,treats,treatment-resistant major depressive disorder,tr-mdd,"""ketamine for treatment-resistant depression: recent development and clinical application."""
2,nefazodone,nefazodone,comparable to,selective serotonin reuptake inhibitors,ssris,"""a meta-analysis of clinical trial compare the serotonin (5ht)-2 receptor antagonist trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder."""
3,bupropion,bupropion,treats,major depressive disorder with high levels of anxiety (anxious depression),anxious mdd,"""efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pool analysis of 10 studies."""
4,vortioxetine,vortioxetine,definition,a novel antidepressant,antidepressant,"""vortioxetine: a novel antidepressant for the treatment of major depressive disorder."""
5,esketamine,intranasal esketamine,treats,treatment-resistant depression,trd,"""intranasal esketamine: a novel drug for treatment-resistant depression."""
6,esketamine,intranasal esketamine,overview,from origin to future implication in treatment-resistant depression,or-trd,"""intranasal esketamine: from origin to future implication in treatment-resistant depression."""
7,riluzole,riluzole combination therapy,treats,moderate-to-severe major depressive disorder,msp-mdd,"""riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial."""
0,ect,electroconvulsive therapy,definition,a medical treatment for severe major depressive disorder,smd treatment,"""electroconvulsive therapy is a medical treatment for severe major depressive disorder"""
1,ect,electroconvulsive therapy,treats,severe major depressive disorder,smd,"""electroconvulsive therapy is a medical treatment for severe major depressive disorder"""
2,ect,electroconvulsive therapy,associated with,psychiatric readmissions in us hospitals,psychiatric readmissions,"""association of electroconvulsive therapy with psychiatric readmissions in us hospitals"""
3,ect,electroconvulsive therapy,benefits,improvement in patient with treatment-resistant smd,treatment-resistant smd improvement,"""improvement after two sessions of electroconvulsive therapy predicts final remission in inpatients with major depression"""
4,ect,electroconvulsive therapy,side effects,risk of dementia,dementia risk,"""electroconvulsive therapy and risk of dementia - a nationwide cohort study in taiwan."""
5,ect,electroconvulsive therapy,highly effective,major depressive disorder with executive dysfunction,mdd with executive dysfunction,"""problem-solve therapy vs supportive therapy in geriatric major depression with executive dysfunction"""
6,exercise,exercise as medicine,definition,a guideline for the treatment of depression recommending physical activity,depression treatment guideline,"""portuguese and brazilian guideline for the treatment of depression: exercise as medicine."""
7,exercise,exercise as medicine,treats,severe major depressive disorder,smd,"""exercise and severe major depression: effect on symptom severity and quality of life at discharge in an inpatient cohort."""
8,exercise,exercise as medicine,associated with,improved quality of life in smd,quality of life improvement,"""exercise and severe major depression: effect on symptom severity and quality of life at discharge in an inpatient cohort."""
0,ect,electroconvulsive therapy,treats,major depressive disorder,mdd,effect of electroconvulsive therapy on depression and its potential mechanism
1,rtms,repetitive transcranial magnetic stimulation,treats,major depressive disorder,mdd,recover from depression with repetitive transcranial magnetic stimulation (rtms): a systematic review and meta-analysis of preclinical study
2,tdcs,transcranial direct current stimulation,treats,major depressive disorder,mdd,clinical research with transcranial direct current stimulation (tdcs): challenge and future direction
3,vns,vagus nerve stimulation,treats,treatment-resistant major depressive disorder,trd,vagus nerve stimulation and depression
4,ect,electroconvulsive therapy,side effects,memory loss,memory loss,"electroconvulsive therapy: mechanism of action, recent advances and limitations"
5,mst,magnetic seizure therapy,treats,major depressive disorder,mdd,magnetic seizure therapy improves mood in refractory major depression
6,light therapy,light therapy,treats,seasonal affective disorder,sad,the efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence
0,mirtazapine,mirtazapine,more effective,"duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine",various antidepressants,"mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratio [or] 1·39), fluoxetine (1·37), fluvoxamine (1·41), paroxetine (1·35), and reboxetine (2·03)."
1,escitalopram,escitalopram,more effective,"duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine",various antidepressants,"mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratio [or] 1·33), fluoxetine (1·32), fluvoxamine (1·35), paroxetine (1·30), and reboxetine (1·95)."
2,venlafaxine,venlafaxine,more effective,"duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine",various antidepressants,"mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratio [or] 1·30), fluoxetine (1·28), fluvoxamine (1·30), paroxetine (1·27), and reboxetine (1·89)."
3,sertraline,sertraline,more effective,"duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine",various antidepressants,"mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratio [or] 1·27), fluoxetine (1·25), fluvoxamine (1·27), paroxetine (1·22), and reboxetine (1·85)."
4,reboxetine,reboxetine,less effective,all other tested antidepressants,antidepressants,reboxetine was significantly less efficacious than all the other antidepressants tested.
5,"escitalopram, sertraline","escitalopram, sertraline",comparable to,each other in acceptability,acceptability,"escitalopram and sertraline show the best profile of acceptability, leading to significantly fewer discontinuations than do duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine."
6,major depression,acute treatment of unipolar major depression,treatment options,"bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine",12 new-generation antidepressants,"for our analysis, we include only randomised control trials that compare any of the following 12 new-generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine) as monotherapy in the acute-phase treatment of adults with unipolar major depression."
0,multiple-treatment meta-analysis,multiple-treatment meta-analysis,definition,a method combining direct and indirect evidence for any given pair of treatments to assess their efficacy and acceptability.,method,this method combine direct and indirect evidence for any give pair of treatment.
1,markov chain monte carlo,markov chain monte carlo methods,used in,bayesian framework for multiple-treatment meta-analysis,bayesian framework,"second, we do a random-effect model within a bayesian framework use markov chain monte carlo method."
2,incoherence,incoherence,definition,the disagreement between direct and indirect evidence with a 95% ci exclude 1 in multiple-treatment meta-analysis.,disagreement,we defined incoherence as the disagreement between direct and indirect evidence with a 95% ci exclude 1.
3,fluoxetine,fluoxetine,example,antidepressant drug,antidepressant,"we express these use fluoxetine as reference drug, because it be the first among these 12 antidepressant to be market in europe and the usa."
4,efficacy and acceptability ranking,efficacy and acceptability ranking,overview,calculated based on the odds ratio for each antidepressant drug compared with an arbitrary common control group within multiple-treatment meta-analyses.,calculation method,we also assess the probability that each antidepressant drug be the most efficacious regiman [...] by calculate the or for each drug compare with an arbitrary common control group.
5,outcomes,outcomes,associated with,the total number of randomly assigned participants,participants,"the analysis be base on the total number of randomly assign participant, irrespective of how the original study investigator analyse the datum."
6,intention-to-treat basis,intention-to-treat basis,definition,"analysis based on the total number of randomly assigned participants, irrespective of how the original study investigators analysed the data.",analysis method,"responder to treatment be calculate on an intention-to-treat basis: the analysis be base on the total number of randomly assign participant, irrespective of how the original study investigator analyse the datum."
0,escitalopram,escitalopram,more effective,citalopram,citalopram,"""efficacy favour escitalopram over citalopram"""
1,citalopram,citalopram,more effective,"reboxetine, paroxetine","reboxetine, paroxetine","""citalopram over reboxetine and paroxetine"""
2,mirtazapine,mirtazapine,more effective,"fluoxetine, venlafaxine","fluoxetine, venlafaxine","""mirtazapine over fluoxetine and venlafaxine"""
3,sertraline,sertraline,more effective,fluoxetine,fluoxetine,"""sertraline over fluoxetine"""
4,venlafaxine,venlafaxine,more effective,"fluoxetine, fluvoxamine","fluoxetine, fluvoxamine","""venlafaxine over fluoxetine and fluvoxamine"""
5,fluoxetine,fluoxetine,side effects,less side effects than reboxetine,reboxetine,"""fluoxetine be well tolerate than reboxetine"""
6,citalopram,citalopram,side effects,less side effects than sertraline,sertraline,"""citalopram than sertraline"""
7,"escitalopram, mirtazapine, sertraline, venlafaxine","escitalopram, mirtazapine, sertraline, venlafaxine",more effective,"duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine","duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine","""escitalopram, mirtazapine, sertraline, and venlafaxine be significantly more efficacious than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine"""
8,reboxetine,reboxetine,less effective,all other antidepressants studied,all other antidepressants,"""reboxetine be significantly less efficacious than all the other 11 antidepressant."""
9,"duloxetine, paroxetine","duloxetine, paroxetine",side effects,less well tolerate than escitalopram and sertraline,"escitalopram, sertraline","""in terms of acceptability, duloxetine and paroxetine be less well tolerate than escitalopram and sertraline."""
0,mirtazapine,mirtazapine,among,the most efficacious treatments,most efficacious treatments,"""mirtazapine, escitalopram, venlafaxine, and sertraline be among the most efficacious treatment"""
1,escitalopram,escitalopram,among,the most efficacious treatments,most efficacious treatments,"""mirtazapine, escitalopram, venlafaxine, and sertraline be among the most efficacious treatment"""
2,venlafaxine,venlafaxine,among,the most efficacious treatments,most efficacious treatments,"""mirtazapine, escitalopram, venlafaxine, and sertraline be among the most efficacious treatment"""
3,sertraline,sertraline,among,the most efficacious treatments,most efficacious treatments,"""mirtazapine, escitalopram, venlafaxine, and sertraline be among the most efficacious treatment"""
4,escitalopram,escitalopram,among,the best tolerated antidepressants,best tolerated antidepressants,"""escitalopram, sertraline, bupropion, and citalopram be well tolerate than the other remain antidepressant"""
5,sertraline,sertraline,among,the best tolerated antidepressants,best tolerated antidepressants,"""escitalopram, sertraline, bupropion, and citalopram be well tolerate than the other remain antidepressant"""
6,bupropion,bupropion,among,the best tolerated antidepressants,best tolerated antidepressants,"""escitalopram, sertraline, bupropion, and citalopram be well tolerate than the other remain antidepressant"""
7,citalopram,citalopram,among,the best tolerated antidepressants,best tolerated antidepressants,"""escitalopram, sertraline, bupropion, and citalopram be well tolerate than the other remain antidepressant"""
8,reboxetine,reboxetine,not effective,as a routine first-line acute treatment for major depression,first-line acute treatment for major depression,"""therefore, reboxetine should not be use as a routine first-line acute treatment for major depression"""
9,mirtazapine,mirtazapine,comparably effective,in terms of efficacy but not the best for overall acceptability,efficacy but not best acceptability,"""these result indicate that two of the most efficacious treatment (mirtazapine and venlafaxine) might not be the good for overall acceptability"""
10,venlafaxine,venlafaxine,comparably effective,in terms of efficacy but not the best for overall acceptability,efficacy but not best acceptability,"""these result indicate that two of the most efficacious treatment (mirtazapine and venlafaxine) might not be the good for overall acceptability"""
11,antidepressants,new-generation antidepressants,treatment options,for acute treatment of major depression,acute treatment of major depression,"""our finding might help to choose among new-generation antidepressant for acute treatment of major depression"""
0,placebo-controlled trials,placebo-controlled trials,definition,"trials mainly designed for regulatory approval purpose; to meet both ethical and safety requirements, they tend to recruit patients with a mild form of disease.",purpose & recruitment criteria,"""placebo-controlled trials are mainly designed for regulatory approval purposes; to meet both ethical and safety requirements, they tend to recruit patients with a mild form of disease."""
1,sponsorship bias,sponsorship bias,definition,the bias associated with the commercial interests of industrial sponsors,bias source,"""evidence exists of the presence of sponsorship bias (ie, the bias associated with the commercial interests of industrial sponsors) in medicine."""
2,sertraline,sertraline,highly effective,new-generation antidepressant drugs,antidepressants,"""our analysis suggests that sertraline is better than other new-generation drugs in terms of efficacy and acceptability."""
3,antidepressants,antidepressants,associated with,potential sponsorship bias,sponsorship bias,"""because most studies comparing the new antidepressants (mirtazapine, escitalopram, bupropion, and duloxetine) were done by the pharmaceutical companies marketing these compounds, this might be a source of bias."""
4,antidepressant trials,antidepressant trials,results,varying response to placebo,response variation,"""response to placebo across antidepressant trials has been shown to vary and have clearly increased in the past two decades, with a similar increase occurring in the fraction of patients responding to active medication as well."""
5,placebo response,placebo response,associated with,inflation of baseline severity,cause,"""inflation of baseline severity, for example, is likely to be a cause for the temporal rise in placebo response rate, which increases the proportion of failed trials."""
0,bupropion xl,bupropion xl,comparable to,escitalopram,escitalopram,"bupropion xl compare with escitalopram : eff ect on sexual functioning and antidepressant efficacy in two randomize , double - blind , placebo control study."
1,venlafaxine,venlafaxine,comparable to,fluoxetine,fluoxetine,a double - blind comparison of venlafaxine and fluoxetine in patient hospitalize for major depression and melancholia.
2,milnacipran,milnacipran,comparable to,fluvoxamine,fluvoxamine,"antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine."
3,bupropion sr,bupropion sustain release,comparable to,sertraline,sertraline,sexual dysfunction associate with the treatment of depression: a placebo - control comparison of bupropion sustain release and sertraline treatment.
4,escitalopram,escitalopram (10 mg/day),comparable to,citalopram (20 mg/day),citalopram,"a randomize, double - blind, 24 - week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patient with major depressive disorder."
5,paroxetine,paroxetine,second-line treatment,major depressive disorder,major depressive disorder,a placebo - control comparison of the antidepressant efficacy and effect on sexual functioning of sustained - release bupropion and sertraline.
6,duloxetine,duloxetine,specific efficacy in treating,major depressive disorder,major depressive disorder,duloxetine in the acute and long - term treatment of major depressive disorder: a placebo- and paroxetine - control trial.
7,venlafaxine xr,venlafaxine xr,comparable to,paroxetine,paroxetine,a comparison of once - daily venlafaxine xr and paroxetine in depressed outpatient treat in general practice.
8,sertraline,sertraline,comparable to,venlafaxine xr,venlafaxine xr,"randomize, double - blind comparison of venlafaxine and sertraline in outpatient with major depressive disorder."
9,escitalopram,escitalopram,comparable to,venlafaxine xr,venlafaxine xr,a randomise study compare escitalopram with venlafaxine xr in primary care patient with major depressive disorder.
10,escitalopram,escitalopram,comparable to,citalopram,citalopram,"prospective, multicentre, randomize, double - blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder."
11,venlafaxine,venlafaxine,comparable to,sertraline,sertraline,probe the safety of medication in the frail elderly: evidence from a randomize clinical trial of sertraline and venlafaxine in depressed nursing home resident.
0,anxious depression,anxious depression,associated with,greater severity of depressive illness and functional impairment,greater severity and impairment,"in patients with high levels of anxiety accompanying major depression, greater severity of depressive illness and functional impairment have been reported."
1,anxious depression,anxious depression,associated with,greater illness chronicity,greater chronicity,"in patients with high levels of anxiety accompanying major depression, greater illness chronicity has been reported."
2,anxious depression,anxious depression,associated with,an increased risk of suicidality,increased suicidality risk,"in patients with high levels of anxiety accompanying major depression, an increased risk of suicidality has been reported."
3,anxious depression,anxious depression,definition,major depressive disorder with high levels of anxiety symptoms,mdd with high anxiety,"anxious depression was defined as major depressive disorder with high levels of anxiety symptoms, as reflected in a ham-d anxiety/somatization factor score ≥7."
4,ham-d,ham-d anxiety/somatization factor score,definition,measures anxiety/somatization in depressed patients,anxiety/somatization measure,"the anxiety/somatization factor, derived from cleary and guy's factor analysis of the ham-d scale, includes six items from the original 17-item version: the items for psychic anxiety, somatic anxiety, gastrointestinal somatic symptoms, general somatic symptoms, hypochondriasis, and insight."
5,citalopram,citalopram,first-line treatment,major depressive disorder,mdd,"a total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in level 1 of star*d."
6,anxious depression,anxious depression,more common than,nonanxious depression,nonanxious depression,"in level 1 of star*d, 53.2% of patients had anxious depression."
7,anxious depression,anxious depression,results,lower remission rates and longer time to remission compared to nonanxious depression,lower remission and longer remission time,remission was significantly less likely and took longer to occur in these patients than in those with nonanxious depression.
8,anxious depression,anxious depression,results,"significantly greater side effects frequency, intensity, and burden",greater side effects,"ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group."
9,anxious depression,anxious depression,definition,associated with poor acute outcomes following antidepressant treatment compared to nonanxious depression,poor outcomes post-treatment,anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment.
0,citalopram,citalopram,definition,a medication used in the treatment of major depressive disorder,treatment,"after an optimal trial of citalopram (based on dose and duration), patients whose symptoms respond or remit could enter the 12-month naturalistic follow-up phase"
1,anxious depression,anxious depression,more common than,nonanxious depression,nonanxious depression,"anxious depression be significantly more common than nonanxious depression among african americans than in other racial/ethnic group; among hispanic than non-hispanic; among those see in primary care setting than those in psychiatric care setting; among those who be unemployed than those who be employ; among those who be married, divorced, or widowed than among those who had never marry; and among those with less education, those with public insurance, and those with less income."
2,anxious depression,anxious depression,results,lower remission rates,lower remission rates,"remission rates be significantly low in patients with anxious depression, according to both the ham-d criterion (22.2% versus 33.4%) and the qids-sr criterion (27.5% versus 38.9%)"
3,side effects,side effects,associated with,discontinuation of citalopram,discontinuation,patients could discontinue citalopram before 12 weeks if intolerable side effects make a medication change necessary
4,citalopram,citalopram,side effects,permitting concomitant treatment,concomitant treatment,"concomitant treatment for current general medical condition, for associated symptom of depression (e.g., sleep and agitation), and for citalopram's side effects be permitted, based on clinical judgment, at study entry or during the treatment."
5,treatment duration,treatment duration with citalopram,details,"0, 2, 4, 6, 9, and 12 weeks, with an optional visit at week 14 if needed",schedule,"the protocol recommends treatment visit at 0, 2, 4, 6, 9, and 12 weeks, with an optional visit at week 14 if need"
6,safety assessment,safety assessment method for monitoring citalopram,definition,a multi-tiered approach involving several roles for monitoring side effects and adverse events,method,"safety assessment to monitor side effects and serious adverse event, a multi- tiered approach be used, involve the clinical research coordinator, the study clinician, the interactive voice response system, the clinical manager, safety officer, regional center director, and the national institute of mental health's data safety and monitoring board"
0,ad,anxious depression,associated with,"greater frequency, intensity, and burden of side effects than nonanxious depression",side effects burden,"""the anxious depression group have great a frequency, intensity, and burden of side ef- fect than the nonanxious depression group"""
1,ad,anxious depression,associated with,more serious adverse events than nonanxious depression,serious adverse events,"""as well as more serious adverse event"""
2,ad,anxious depression,associated with,more hospitalizations for general medical conditions compared with nonanxious depression,hospitalizations,"""notably, the num- ber of hospitalization for ge neral medical condition be strikingly different between the two group"""
3,ad,anxious depression,results,longer time to remission and response on average than nonanxious depression,longer time to remission,"""the time to first remission and first response differ significantly between the anxious and nonanxious depression group"""
4,citalopram,citalopram,treats,symptoms in level 1 of star*d in nonanxious depression more effectively than in anxious depression,symptoms in nonanxious depression,"""patient withanxious depression be less likely to respond or to remit with citalopram treatment than those with nonanxious depression"""
5,sr bupropion,sustained-release bupropion,dosage,up to 400 mg per day,400 mg/day,"""to sustain - release bupropion ( at a dose of up to 400 mg per day"""
6,sertraline,sertraline,dosage,maximal daily dose of 200 mg,200 mg/day,"""sertraline ( at a maximal daily dose of 200 mg"""
7,xr venlafaxine,extended-release venlafaxine,dosage,maximal daily dose of 375 mg,375 mg/day,"""extend - re- lease venlafaxine ( at a maximal daily dose of 375 mg"""
8,buspirone,buspirone,dosage,up to 60 mg per day,60 mg/day,"""bus- pirone ( at a dose of up to 60 mg per day"""
9,ad,anxious depression,results,less likely to achieve remission,lower remission rates,"""patient with anxious depression be also less likely than those with nonanxious depre - sion to achieve remission"""
0,anxious depression,anxious depression,associated with,greater side effect burden,greater side effect burden,"side effect frequency , intensity , and burden in level 1 be great among patient with anxious depression thanamong those with nonanxious depression"
1,nonanxious depression,nonanxious depression,associated with,lower side effect burden,lower side effect burden,"side effect frequency , intensity , and burden in level 1 be great among patient with anxious depression thanamong those with nonanxious depression"
2,anxious depression,anxious depression,associated with,serious adverse events,serious adverse events,"as be serious adverse event , include those of a psychiatric nature"
3,anxious depression,anxious depression,results,lower remission rates,lower remission rates,patient with this subtype be less likely to achieve remission than those with nonanxious depression after antidepressant treatment
4,nonanxious depression,nonanxious depression,results,higher remission rates,higher remission rates,patient with this subtype be less likely to achieve remission than those with nonanxious depression after antidepressant treatment
5,anxious depression,anxious depression,symptom,physical symptom sensitivity,physical symptom sensitivity,perhaps patient whose illness include anxious feature be more sensitive to somatic change occur during antidepressant treatment
6,ms. d's case,ms. d's case,associated with,worsening of insomnia and nervousness,worsening of insomnia and nervousness,"within a few day of start the medication , she call we express her concern about the side effect that she be experience ; in particular , she be worried about the worsening of her insomnia and her nervousness"
7,anxious depression,anxious depression,definition,major depressive disorder with prominent anxiety features,mdd with anxiety features,"in this and our two previousstudie , anxious depression appear to be associate with a characteristic clinical profile , independent ofseverity of depression"
8,citalopram,citalopram,treats,anxious depression,anxious depression,ms . d be start on a course of antidepressant therapy with citalopram
